Aquestive Therapeutics, Inc. (AQST)

NASDAQ: AQST · IEX Real-Time Price · USD
4.180
-0.060 (-1.42%)
At close: Mar 4, 2024, 4:00 PM
4.250
+0.070 (1.67%)
After-hours: Mar 4, 2024, 6:29 PM EST
-1.42%
Market Cap 283.09M
Revenue (ttm) 48.06M
Net Income (ttm) -12.11M
Shares Out 66.77M
EPS (ttm) -0.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 5,344,563
Open 4.920
Previous Close 4.240
Day's Range 4.000 - 4.960
52-Week Range 0.720 - 4.960
Beta 2.84
Analysts Strong Buy
Price Target 6.00 (+43.54%)
Earnings Date Mar 5, 2024

About AQST

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with che... [Read more]

Sector Healthcare
IPO Date Jul 25, 2018
Employees 130
Stock Exchange NASDAQ
Ticker Symbol AQST
Full Company Profile

Financial Performance

In 2022, AQST's revenue was $47.68 million, a decrease of -6.20% compared to the previous year's $50.83 million. Losses were -$54.41 million, -22.87% less than in 2021.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for AQST stock is "Strong Buy." The 12-month stock price forecast is $6.0, which is an increase of 43.54% from the latest price.

Price Target
$6.0
(43.54% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Aquestive Therapeutics to Report Fourth Quarter 2023 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET

WARREN, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement...

12 days ago - GlobeNewsWire

Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data at the 2024 AAAAI Annual Meeting

WARREN, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement...

18 days ago - GlobeNewsWire

Aquestive Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Conference

WARREN, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through inn...

4 weeks ago - GlobeNewsWire

Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm™ (epinephrine) Sublingual Film

WARREN, N.J., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement...

3 months ago - GlobeNewsWire

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for Anaphylm™ at American College of Allergy Asthma and Immunology (ACAAI) Annual Meeting

WARREN, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement...

4 months ago - GlobeNewsWire

Aquestive Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

WARREN, N.J., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through inno...

4 months ago - GlobeNewsWire

Aquestive Therapeutics Completes $45 Million Debt Refinancing

WARREN, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through inno...

4 months ago - GlobeNewsWire

Aquestive Therapeutics Provides Business Update

WARREN, N.J., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and ...

5 months ago - GlobeNewsWire

Aquestive Therapeutics Reaffirms Timeline and Pathway for Anaphylm™ (epinephrine) Sublingual Film

WARREN, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and...

5 months ago - GlobeNewsWire

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

WARREN, N.J., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients' problems wit...

6 months ago - GlobeNewsWire

Aquestive Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

WARREN, N.J., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and ...

7 months ago - GlobeNewsWire

Aquestive Therapeutics to Participate in 2023 Wedbush PacGrow Healthcare Conference

WARREN, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients' problems wit...

7 months ago - GlobeNewsWire

Aquestive Therapeutics to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 7 and Host Conference Call on August 8 at 8:00 a.m. ET

WARREN, N.J., July 25, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients' problems wi...

7 months ago - GlobeNewsWire

Aquestive Therapeutics to Present Positive Topline Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm ™ (epinephrine) Sublingual Film at Aspen Allergy Conference

WARREN, N.J., July 25, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients' problems wit...

7 months ago - GlobeNewsWire

Aquestive Therapeutics Provides Business Update and Announces Chief Medical Officer Appointment

WARREN, N.J., June 29, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients' problems wit...

8 months ago - GlobeNewsWire

Aquestive Therapeutics Reports Positive Results from Latest Clinical Studies Evaluating Pharmacokinetic and Pharmacodynamic Performance of Anaphylm ™ (epinephrine) Sublingual Film and Provides Findings from Recent Auto-Injector Clinical Study

WARREN, N.J., May 31, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients' problems with...

9 months ago - GlobeNewsWire

Aquestive Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

WARREN, N.J., May 02, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and p...

10 months ago - GlobeNewsWire

Aquestive Therapeutics Expands License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal Film to Additional Global Markets

WARREN, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and...

1 year ago - GlobeNewsWire

Aquestive Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Business Update on Key 2023 Objectives

WARREN, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and...

1 year ago - GlobeNewsWire

Aquestive Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference

WARREN, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care an...

1 year ago - GlobeNewsWire

Aquestive Therapeutics to Report Fourth Quarter 2022 Financial Results and Recent Business Highlights on March 7 and Host Conference Call on March 8 at 8:00 a.m. ET

WARREN, N.J., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients' problems wi...

1 year ago - GlobeNewsWire

Aquestive Therapeutics Provides Business Update and Outlines Key 2023 Objectives

WARREN, N.J., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients' problems wit...

1 year ago - GlobeNewsWire

Aquestive Therapeutics Announces Completion of FDA End-of-Phase 2 Meeting For AQST-109 (epinephrine sublingual film)

WARREN, N.J., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients' problems wit...

1 year ago - GlobeNewsWire

Aquestive Therapeutics Announces Publication of Crossover Food Effect Study of Diazepam Nasal Spray in Epilepsia

Peer-reviewed data indicates that food significantly decreases and delays the absorption of diazepam dosed via nasal spray Peer-reviewed data indicates that food significantly decreases and delays the...

1 year ago - GlobeNewsWire

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic Studies for AQST-109 (epinephrine sublingual film) at American Academy of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting

WARREN, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients' problems through simplifyin...

1 year ago - GlobeNewsWire